Experimental Drug for Rheumatoid Arthritis Shows Promise

THURSDAY, March 31, 2016 -- An experimental drug to treat rheumatoid arthritis showed promise in a new six-month trial. Baricitinib substantially reduced symptoms and improved daily physical functioning among people who failed other treatments for...
Source: Drugs.com - Daily MedNews - Category: Journals (General) Source Type: news

Related Links:

ConclusionThe concentrations of HDLC, TG and LDLC were associated with the concentration of anti-CCP, RF, CRP and ESR in RA patients. Therefore, clinical diagnosis of RA and determination of disease activity should consider the impact of the concentration of serum lipids in order to make a reasonable judgment on the diagnosis of the disease.
Source: Clinica Chimica Acta - Category: Laboratory Medicine Source Type: research
Authors: Vitales-Noyola M, Layseca-Espinosa E, Baranda L, Abud-Mendoza C, Niño-Moreno P, Monsiváis-Urenda A, Rosenstein Y, González-Amaro R Abstract We assessed different immune parameters in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) with low (LSI) and high (HSI) sodium intake. Thirty-eight patients with RA, thirty-seven with SLE, and twenty-eight healthy subjects were studied and classified as LSI or HSI. Levels and suppressive function of CD4+CD25+Foxp3+ and CD4+CD69+Foxp3- Treg cells were determined by flow cytometry in blood samples. Levels and in vitro ...
Source: Journal of Immunology Research - Category: Allergy & Immunology Tags: J Immunol Res Source Type: research
Publication date: Available online 18 August 2018Source: Reumatología Clínica (English Edition)Author(s): Luis María Jiménez Liñán, Sergio Antonio Rodríguez Montero, José Luis Marenco de la Fuente
Source: Reumatologia Clinica - Category: Rheumatology Source Type: research
Authors: Berekmeri A, Mahmood F, Wittmann M, Helliwell P Abstract INTRODUCTION: Psoriasis and psoriatic arthritis (PsA) are inflammatory immune mediated conditions which can cause considerable disability and reduced quality of life. Management can be complex as clinical heterogeneity may lead to different treatment pathways. Tofacitinib is a novel, oral janus kinase (JAK) inhibitor with proven efficacy in rheumatoid arthritis. Areas covered: This review analyses recent studies of tofacitinib in psoriatic disease treatment. The relevant literature was identified using clinicaltrials.gov, PubMed and Google Scholar. T...
Source: Expert Review of Clinical Immunology - Category: Allergy & Immunology Tags: Expert Rev Clin Immunol Source Type: research
ConclusionsAlthough there was an acceptable correlation between the presence of subclinical atherosclerosis and SCOREM, there was a considerable proportion of atheromatous plaques in low-risk patients. Disease activity was the risk factor most closely associated with increased CVR.ResumenLa artritis reumatoide (AR) presenta una mortalidad de 1,3 a 3 veces superior a la población general; la principal causa de muerte son las complicaciones cardiovasculares (40-50%). En el abordaje inicial se debe incluir la valoración del riesgo cardiovascular (RCV) mediante algoritmos adaptados para esta población. Si ...
Source: Reumatologia Clinica - Category: Rheumatology Source Type: research
RHEUMATOID arthritis symptoms include joint pain, inflammation and restricted movement. But the autoimmune condition can cause other warning signs in different parts of the body. These are the uncommon symptoms to watch out for.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Conclusion: Wrist arthrodesis using an LCP metaphyseal plate was favorable for rheumatoid arthritis patients with comparable stability to that of and a lower risk of plate-related complications than an AO wrist fusion plate. PMID: 30112006 [PubMed]
Source: International Journal of Rheumatology - Category: Rheumatology Tags: Int J Rheumatol Source Type: research
Conclusion: Gum Arabic has favorable immune modulator effect on rheumatoid arthritis. It can be utilized in clinical practice as adjuvant therapy. Trial Registration: This trial was registered with ClinicalTrials.gov Identifier: NCT02804581 Registered at 19 June 2016, prospective registration. PMID: 30112005 [PubMed]
Source: International Journal of Rheumatology - Category: Rheumatology Tags: Int J Rheumatol Source Type: research
In the original publication, the family name of the last author was incorrect. The correct name should read as Jaime Calvo-Al én.
Source: Rheumatology International - Category: Rheumatology Source Type: research
AbstractFatigue has a large impact on quality of life and is still unmanageable for many patients. Study aims were describe (1) the prevalence and pattern of fatigue over time in patients with early rheumatoid arthritis under a treat-to-target strategy and (2) identify predictive factors for worsening and recovering of fatigue over time. Data from the tREACH study were used, comparing different treatment strategies with fatigue as secondary objective. Patient outcomes on fatigue, quality of life, depression, and coping were obtained every 6  months and clinically assessed every 3 months. Prediction of fatigue at ...
Source: Rheumatology International - Category: Rheumatology Source Type: research
More News: Arthritis | General Medicine | Rheumatoid Arthritis | Rheumatology